| Identification | Back Directory | [Name]
Danirixin | [CAS]
954126-98-8 | [Synonyms]
CS-2750
CS-1940
Danirixin
GSK1325756
Danirixin HCl
Danirixin (GSK1325756)
Solabegron Hydrochloride
1-[4-Chloro-2-hydroxy-3-(piperidine-3-sulfonyl)-phenyl]-3-(3-fluoro-2-methyl-phenyl)-urea
N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N'-(3-fluoro-2-methylphenyl)urea
Urea, N-[4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N'-(3-fluoro-2-methylphenyl)- | [Molecular Formula]
C19H21ClFN3O4S | [MDL Number]
MFCD27987922 | [MOL File]
954126-98-8.mol | [Molecular Weight]
441.9 |
| Chemical Properties | Back Directory | [Melting point ]
>153°C (dec.) | [Boiling point ]
533.1±50.0 °C(Predicted) | [density ]
1.467±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Methanol (Slightly) | [form ]
Solid | [pka]
4.95±0.10(Predicted) | [color ]
White to Light Brown |
| Hazard Information | Back Directory | [Uses]
Antidiabetic (β3 adrenoreceptor agonist). | [Biological Activity]
Danirixin (GSK1325756) is an orally activeselective CXC chemokine receptor 2 (CXCR2) antagonist with 78-fold lower affinity toward CXCR1 (CXCR2/CXCR1 IC50 = 12.5/977 nM by competitive binding against 0.225 nM [125I] CXCL8). Danirixin blocks agonist-induced neutrophil CD11b expression in vitro (IC50 = 420/890 nM against induction by 10 nM human CXCL1/r at CXCL2 using rat/human whole blood) and prevents lung neutrophils influx in rats in vivo following aerosol lipopolysaccharide or ozone challenge (ED50 = 1.4 and 16 mg/kgrespectively). |
|
|